Datum | Källa | Rubrik | Typ | Alternativ | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-07-10 | Nanexa | Sommarbrev från Nanexa | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-07-10 | Nanexa | Summer letter from Nanexa | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-06-09 | Nanexa | Bulletin from Nanexa’s Annual General Meeting 2023 | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-06-09 | Nanexa | Kommuniké från årsstämma i Nanexa | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-06-09 | Nanexa | Nanexa har slutfört den planerade rekryteringen till Fas 1-studien av NEX-20 | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-06-09 | Nanexa | Nanexa has completed the planned recruitment to the Phase 1 study of NEX-20 | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-06-01 | Nanexa | Nanexa skriver kontrakt med internationellt ledande CRO inom diabetes för fas I-studie med NEX-22 | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-06-01 | Nanexa | Nanexa signs contract with leading international diabetes CRO for Phase I study with NEX-22 | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-05-22 | Redeye | Redeye: Nanexa - Moments of truth closing in | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-05-10 | Nanexa | Kallelse till årsstämma i Nanexa AB | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-05-10 | Nanexa | Notice of Annual General Meeting in Nanexa AB | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
Pressreleaser |
Notice of Annual General Meeting in Nanexa ABThe shareholders in Nanexa AB (publ) reg. no. 556833–0285 (the “Company”) are hereby given notice that the annual general meeting will be held on Friday 9 June 2023, at 10:00am at Uppsala Business Park, Rapsgatan 7, Uppsala, Sweden. Right to participate at the general meeting
Nominee-registered shares Proxy Number of shares and votes Proposed agenda Resolution proposals Item 1 – Opening of the meeting and election of the chairman for the meeting The nomination committee for the 2023 annual general meeting has consisted of Philip Norin, Hanno Lindroth (appointed by Mårten Rooth), Christian Östberg (appointed by Anders Johansson) and Göran Ando (chairman of the board), co-opted. Item 8b) – Dispositions regarding the Company’s result according to the approved balance sheet Item 9 – Determination of remuneration to the board of directors and the auditor Item 10 – Election of the board of directors and auditor The nomination committee proposes that Göran Ando is re-elected as chairman of the board. Jakob Dynnes Hansen has 30 years of combined experience from biotech and financing. Jakob currently holds the position as CFO for the Danish company Zerion Pharma A/S and the Swedish company Asarina Pharma AB. His previous experience includes CFO for more than 9 years at Evolva, a Swiss public biotech company, where he played a key role in the company’s listing and several subsequent financings. Prior to that, Jakob was CFO at Danish biotech companies Nuevolution and Zealand Pharma and, before moving into biotech, he was a senior member of the Corporate Finance Team at Unibank (now Nordea) and he has been Head of Market Research at Novo Nordisk. Mr Hansen has an MSc in Economics from University of Copenhagen and an MBA from INSEAD. The nomination committee proposes re-election of Öhrlings PricewaterhouseCoopers AB as auditor. Chartered accountant Niclas Bergenmo will in such a case continue as principal auditor. Item 11 – Establishment of a nomination committee and adoption of instructions for the nomination committee The general meeting instructs the chairman of the board to contact the three largest shareholders in terms of votes according to Euroclear Sweden AB’s printout of the share register as of 30 September 2023, who each appoint a member of the nomination committee. In the event that any of the three largest shareholders does not wish to appoint a member of the nomination committee, the fourth largest shareholder shall be consulted and so on until the nomination committee consists of three members. However, not more than ten shareholders need to be consulted. Furthermore, the chairman of the board shall be co-opted to the nomination committee. The members of the nomination committee shall be published on the Company’s website no later than six months before the next annual general meeting. The term of office for the appointed nomination committee shall run until a new nomination committee has been appointed in accordance with the mandate from the next annual general meeting. The nomination committee appoints a chairman from among its members. The chairman of the board or another board member shall not be the chairman of the nomination committee. If a member leaves the nomination committee before its term is completed, and if the nomination committee considers that there is a need to replace this member, the nomination committee shall appoint a new member in accordance with the principles above, but based on Euroclear Sweden AB’s printout of the share register as soon as possible after the member has left its post. Changes in the composition of the nomination committee shall be announced immediately. No remuneration shall be paid to the committee members for their work on the nomination committee. The Company shall however bear reasonable costs that arise in the nomination process. The nomination committee shall submit proposals for resolutions on the following issues to the 2024 annual general meeting: Item 12 – Resolution on amendment of the Company’s articles of association
The CEO, or any other person appointed by the board of directors, shall have the right to make such minor adjustments to this resolution that may be necessary in connection with the registration with the Swedish Companies Registration Office and Euroclear Sweden AB. A resolution in accordance with the proposal requires that the resolution is supported by shareholders representing at least two-thirds of both the votes cast and the shares represented at the meeting. Item 13 – Resolution on authorization (rights issue) Item 14 – Resolution on authorization (directed issue) The reason to propose that the board of directors shall be authorized to resolve on issues with deviation from the shareholder’s preferential rights and/or with provisions on payment by non-cash consideration, by way of set-off or other provisions in accordance with above, is that the Company shall be able to issue shares, warrants and/or convertible instruments with the purpose of acquiring new capital and to enable the board of directors to direct issues to investors that the board of directors deems to be strategically important for the Company. A resolution in accordance with the proposal requires that the resolution is supported by shareholders representing at least two-thirds of both the votes cast and the shares represented at the meeting. Item 15 – Resolution to implement a warrant-based incentive program for all employees
Additional information Dilution and information on outstanding share-related incentive programs If the general meeting resolves on an issue in accordance with this proposal, the issue is fully subscribed and all warrants are exercised for subscription of shares, the number of shares and votes in the Company will increase by 1,345,000 (with reservation for eventual recalculation according to the Terms), which corresponds to a dilution of approximately 2.17 percent of the number of shares and votes in the Company. There are four outstanding share-related incentive programs in the Company since before – warrant program 2020/2023:1, warrant program 2020/2023:2, warrant program 2021/2024:1 and warrant program 2022/2025. Per the day of this proposal there are 392,000 outstanding warrants in warrant program 2020/2023:1 (warrants of series 2020/2023:1 (TO 3)), which are held by employees, 724,000 outstanding warrants in warrant program 2020/2023:2 (warrants of series 2020/2023:2) (TO 4)), which are held by board members, 380,000 outstanding warrants in warrant program 2021/2024:1 (warrants of series 2021/2024:1 (TO 5)), which are held by employees, and 983,000 outstanding warrants in warrant program 2022/2025 (warrants of series 2022/2025 (TO 6)), which are held by employees. Each warrant of series 2020/2023:1 (TO 3) and series 2020/2023:2 (TO 4) entitles (after recalculation according to the terms and conditions for the programs) to subscription of 1.02 new shares in the Company at a subscription price of SEK 15.79 during the period from 1 June 2023 up to and including 31 July 2023. Each warrant of series 2021/2024:1 (TO 5) entitles (after recalculation according to the terms and conditions for the program) to subscription of 1.02 new shares in the Company at a subscription price of SEK 12.67 during the period from 15 June 2024 up to and including 31 July 2024. Each warrant of series 2022/2025 (TO 6) entitles to subscription of one new share in the Company at a subscription price of SEK 4.95 during the period from 15 June 2025 up to and including 31 July 2025. If (i) all warrants that are outstanding in warrant programs 2020/2023:1, 2020/2023:2, 2021/2024:1 and 2022/2025 are exercised for subscription of shares, (ii) the general meeting resolves to implement Warrant Program 2023/2026 in accordance with the board of directors’ proposal, (iii) the issue is fully subscribed and all warrants in Warrant Program 2023/2026 are exercised for subscription of shares, the number of shares and votes in the Company will increase by 3,853,920 (with reservation for eventual recalculation according to the terms and conditions of the respective program), which corresponds to a total dilution of approximately 5.97 percent of the number of shares and votes in the Company. The dilution effects have been calculated as the number of additional shares and votes in relation to the number of existing shares and votes plus the number of additional shares and votes. Preliminary valuation, costs and effects on key figures Since the warrants shall be issued to the employees at market value, Warrant Program 2023/2026 is not expected to incur any accounting costs for the Company, nor any costs in the form of social security contributions or the like. The Company will subsidize the amount that the participants in Warrant Program 2023/2026 shall pay for the warrants through extra gross salary allowances corresponding to 100 percent of the warrant premiums. 50 percent of the subsidy shall be paid in connection with the allotment of the warrants. The remaining 50 percent of the subsidy shall be paid one year after the allotment of the warrants. A participant’s right to receive the second half of the subsidy is conditional on that the participant has neither given nor received any notice of termination of his/her employment, nor has transferred his/her warrants, at the time when the subsidy is paid. The total cost of the subsidy, based on the preliminary option value mentioned above, is estimated to amount to approximately SEK 1,098,000, including costs for social security contributions. The warrants are expected to have a marginal effect on the Company’s key figures. Preparation of the proposal Majority requirements Processing of personal data In connection with the annual general meeting, personal data will be processed in accordance with the Company’s privacy policy, available on the Company’s website www.nanexa.com. Questions to the board of directors and the CEO The board of directors and the CEO shall, if requested by any shareholder and if the board is of the opinion that it can be done without causing material harm to the Company, provide information regarding circumstances that may affect the assessment of an item on the agenda or circumstances that may affect the assessment of the Company’s financial situation. Provision of documents The annual report and the auditor’s report as well as other documents in accordance with the Swedish Companies Act will be available at the Company and on the Company’s website, www.nanexa.com, no later than Friday 19 May 2023. The documents are also sent free of charge to shareholders who so request and who provide their address. Uppsala in May 2023 Nanexa AB (publ) The Board of Directors |
||||||||||||||||||
2023-05-05 | Emergers | Emergers: Equity Research | NANEXA: Solid progress in development into 2023, with funding needs on the horizon | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-05-04 | Nanexa | Nanexa publishes interim report for January – March 2023 | Rapporter | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-05-04 | Nanexa | Nanexa publicerar delårsrapport för januari-mars 2023 | Rapporter | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-05-03 | Nanexa | Nanexa publicerar årsredovisning för 2022 | Rapporter | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-05-03 | Nanexa | Nanexa publishes annual report for 2022 | Rapporter | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-03-23 | Nanexa | NEX-22 preclinical data shows controlled release of liraglutide for one month | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-03-23 | Nanexa | Prekliniska data av NEX-22 bekräftar kontrollerad frisättning av liraglutid i en månad | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-02-23 | Emergers | Emergers: NANEXA: 90 Second Pitch with CEO David Westberg | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-02-17 | Redeye | Redeye: Nanexa Q4 2022 - A Stronger Case | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-02-17 | Emergers | Emergers: Equity Research | NANEXA: Validation from Novo Nordisk positions Nanexa for an eventful year ahead | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-02-16 | Nanexa | Nanexa publishes year-end report for 2022 | Rapporter | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-02-16 | Nanexa | Nanexa publicerar bokslutskommuniké för 2022 | Rapporter | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-02-15 | Nanexa | Inbjudan till presentation av Nanexas bokslutskommuniké och Q4-rapport | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-02-15 | Nanexa | Invitation to presentation of Nanexa’s year-end report and Q4-report | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-02-08 | Nanexa | Nanexa participates at the 4th annual “Beyond Medicines’ Barriers Meeting”, arranged by the International Myeloma Foundation | Analyser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-02-08 | Nanexa | Nanexa deltar på 4th annual “Beyond Medicines’ Barriers Meeting”, arrangerat av International Myeloma Foundation | Analyser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2022-12-23 | Emergers | Emergers: Equity Research | NANEXA: Novo Nordisk deal offers both scientific validation and investor-friendly financing | Analyser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2022-12-21 | Nanexa | Inbjudan till nyhetskommentar med anledning av Nanexas nyhetssläpp den 21 december 2022 | Analyser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2022-12-21 | Nanexa | Invitation to commentary regarding Nanexa's press release on 21 December 2022 | Analyser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2022-12-21 | Nanexa | Nanexa signs an exclusivity and evaluation agreement worth SEK 46.1 million and completes a directed share issue of SEK 17.2 million to Novo Nordisk | Analyser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2022-12-21 | Nanexa | Nanexa tecknar ett exklusivitets- och utvärderingsavtal värt 46,1 MSEK och genomför en riktad emission till Novo Nordisk om 17,2 MSEK | Analyser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2022-12-06 | Nanexa | Nanexa har startat Fas 1-studien med NEX-20 enligt plan | Analyser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2022-12-06 | Nanexa | Nanexa has started the Phase 1 study of NEX-20 according to plan | Analyser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2022-11-16 | Nanexa | Nanexa AB och VitriVax, Inc. har nått en lösning på patentintrångsprocessen | Analyser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2022-11-16 | Nanexa | Nanexa AB and VitriVax, Inc. have resolved the patent infringement lawsuit | Analyser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2022-11-14 | Nanexa | Nanexa receives approval to start clinical trial with NEX-20 | Analyser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2022-11-14 | Nanexa | Nanexa erhåller godkännande att starta klinisk studie med NEX-20 | Analyser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2022-11-10 | Nanexa | Valberedning inför Nanexa AB (publ) årsstämma 2023 | Analyser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2022-11-10 | Nanexa | Nomination Committee for Nanexa AB (publ) Annual General Meeting 2023 | Analyser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2022-10-26 | Emergers | Emergers: Equity Research | NANEXA: Charging to enter triple clinical trials in the coming year | Analyser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2022-10-25 | Nanexa | Nanexa publishes interim report for January – September 2022 | Analyser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2022-10-25 | Nanexa | Nanexa publicerar delårsrapport för januari-september 2022 | Analyser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2022-10-24 | Nanexa | Inbjudan till presentation av Nanexas Q3-rapport 2022 | Analyser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2022-10-21 | Nanexa | Nanexa tecknar utvärderingsavtal med läkemedelsbolag specialiserat inom ögonområdet | Analyser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2022-10-21 | Nanexa | Nanexa signs evaluation agreement with a Speciality Pharma company | Analyser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2022-09-27 | Nanexa | Nanexa AB och Vitrivax, Inc har nått en överenskommelse i alla väsentliga delar | Analyser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2022-09-27 | Nanexa | Nanexa AB and Vitrivax, Inc reach agreement in principle | Analyser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2022-09-19 | Emergers | Emergers: NANEXA Equity Research Case Video Summary | Analyser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2022-09-16 | Emergers | Emergers: Equity Research | NANEXA: New project NEX-22 to add significant daily benefits for 50m patient market | Analyser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2022-09-15 | Nanexa | Nanexa startar produktprojektet NEX-22 som adresserar en enorm marknad | Analyser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2022-09-15 | Nanexa | Nanexa launches NEX-22 product project to address a huge market | Analyser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2022-08-30 | Nanexa | Nanexa tecknar utvärderingsavtal med ett stort globalt läkemedelsbolag | Analyser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2022-08-30 | Nanexa | Nanexa signs evaluation agreement with a Global Pharmaceutical Company | Analyser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2022-08-29 | Redeye | Redeye: Nanexa - Our Q2 Comment | Analyser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2022-08-26 | Nanexa | Nanexa publishes interim report for January – June 2022 | Analyser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2022-08-26 | Nanexa | Nanexa publicerar delårsrapport för januari-juni 2022 | Analyser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2022-08-25 | Nanexa | Nanexa receives extended GMP-certificate for the new pilot plant | Analyser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2022-08-25 | Nanexa | Nanexa erhåller utökat GMP certifikat för den nya pilotanläggningen | Analyser | Ladda ner | Visa Stäng | ||||||||||||||
|